Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Blood (2018) 132 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2018-99-112847

Published: 2018

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD

Blood (2016) 128 (22): 182.

https://doi.org/10.1182/blood.V128.22.182.182

Published: 2016

Journal Articles

Response Of Rare Variants Of Cutaneous T Cell Lymphoma (CTCL) To Treatment With Bexarotene. A Prospective German DeCOG Trial

Blood (2013) 122 (21): 4379.

https://doi.org/10.1182/blood.V122.21.4379.4379

Published: 2013

Journal Articles

PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

Blood (2013) 122 (15): 2683–2693.

https://doi.org/10.1182/blood-2013-04-497933

Published: 2013

Includes: Supplemental data

Journal Articles

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Blood (2011) 118 (15): 4024–4035.

https://doi.org/10.1182/blood-2011-05-351346

Published: 2011

Journal Articles

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Maria B. Karpova, Marie C. Zipser, William M. Lin, Michael Girardi, Laura E. MacConaill, Sarah M. Kehoe, Charlie Hatton, Lars E. French, Levi A. Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H. Krammer, Karsten Gülow, Reinhard Dummer

Blood (2011) 117 (8): 2433–2440.

https://doi.org/10.1182/blood-2010-09-305128

Published: 2011

Includes: Supplemental data

Journal Articles

EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.

Reinhard Dummer, Sean Whittaker, Baktiar Hasan, Juergen C Becker, Michael Weichenthal, Rudolf Stadler, Matthias Karrasch, Martine Bagot, Robert Knobler, Maria Bernengo

Blood (2010) 116 (21): 2823.

https://doi.org/10.1182/blood.V116.21.2823.2823

Published: 2010

Journal Articles

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Jürgen C. Becker, Stephane Dalle, Francisco Vanaclocha, Maria Grazia Bernengo, Celeste Lebbé, Reinhard Dummer, Samit Hirawat, Lei Zhang, Miriam Marshood, Glen Laird, H. Miles Prince

Blood (2008) 112 (11): 1005.

https://doi.org/10.1182/blood.V112.11.1005.1005

Published: 2008

Journal Articles

Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology.

Blood (2008) 112 (11): 1769.

https://doi.org/10.1182/blood.V112.11.1769.1769

Published: 2008

Journal Articles

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Nancy J. Senff, Evert M. Noordijk, Youn H. Kim, Martine Bagot, Emilio Berti, Lorenzo Cerroni, Reinhard Dummer, Madeleine Duvic, Richard T. Hoppe, Nicola Pimpinelli, Steven T. Rosen, Maarten H. Vermeer, Sean Whittaker, Rein Willemze

Blood (2008) 112 (5): 1600–1609.

https://doi.org/10.1182/blood-2008-04-152850

Published: 2008

Journal Articles

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood (2007) 110 (6): 1713–1722.

https://doi.org/10.1182/blood-2007-03-055749

Published: 2007

Includes: Supplemental data

Journal Articles

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Youn H. Kim, Rein Willemze, Nicola Pimpinelli, Sean Whittaker, Elise A. Olsen, Annamari Ranki, Reinhard Dummer, Richard T. Hoppe

Blood (2007) 110 (2): 479–484.

https://doi.org/10.1182/blood-2006-10-054601

Published: 2007

Includes: Supplemental data

Journal Articles

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

Lucie Heinzerling, Valerie Künzi, Patrick A. Oberholzer, Thomas Kündig, Hussein Naim, Reinhard Dummer

Blood (2005) 106 (7): 2287–2294.

https://doi.org/10.1182/blood-2004-11-4558

Published: 2005

Journal Articles

Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas

Reinhard Dummer, Jessica C. Hassel, Friederike Fellenberg, Stefan Eichmüller, Tanja Maier, Philippe Slos, Bruce Acres, Pascal Bleuzen, Vincent Bataille, Patrick Squiban, Günter Burg, Mirjana Urosevic

Blood (2004) 104 (6): 1631–1638.

https://doi.org/10.1182/blood-2004-01-0360

Published: 2004

Journal Articles

Primary cutaneous CD8 + and CD56 + T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2

Mirjana Urosevic, Jivko Kamarashev, Günter Burg, Reinhard Dummer

Blood (2004) 103 (5): 1796–1798.

https://doi.org/10.1182/blood-2003-10-3372

Published: 2004

Journal Articles

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

Tanja Maier, Adrian Tun-Kyi, Anatoli Tassis, Karl-Peter Jungius, Günter Burg, Reinhard Dummer, Frank O. Nestle

Blood (2003) 102 (7): 2338–2344.

https://doi.org/10.1182/blood-2002-08-2455

Published: 2003

Journal Articles

Functional expression of the eotaxin receptor CCR3 in CD30 + cutaneous T-cell lymphoma

Martin Kleinhans, Adrian Tun-Kyi, Michel Gilliet, Marshall E. Kadin, Reinhard Dummer, Günter Burg, Frank O. Nestle

Blood (2003) 101 (4): 1487–1493.

https://doi.org/10.1182/blood-2002-02-0475

Published: 2003

Journal Articles

HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas

Mirjana Urosevic, Joerg Willers, Beatrix Mueller, Werner Kempf, Guenter Burg, Reinhard Dummer

Blood (2002) 99 (2): 609–617.

https://doi.org/10.1182/blood.V99.2.609

Published: 2002

NARROW

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Response Of Rare Variants Of Cutaneous T Cell Lymphoma (CTCL) To Treatment With Bexarotene. A Prospective German DeCOG Trial

PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology.

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas

Primary cutaneous CD8 + and CD56 + T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

Functional expression of the eotaxin receptor CCR3 in CD30 + cutaneous T-cell lymphoma

HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only